Abeona Therapeutics Inc. (ABEO)
ABEONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$2.71
-1.46 (-35.03%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $145.25m
- P/E
- –
- EPS, last 4 quarters
- $-1.09
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.91 to $7.65
- Average volume
- 1.20m
- Previous close
- $4.17
Analysts
3 coveringStrong Buy3 buy, 0 hold, 0 sell
Targets a year out average $22.00, +712.0% from here
Earnings
next estimate $-0.1400Next report Nov 11, 2026
Sep 2025
+63.0%
Dec 2025
+2.9%
Mar 2026
+9.1%
Jun 2026
-52.2%
estimate reported, and the surprise
Financials
| Quarter | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $400.0k | $25.62m | $8.72m | $11.38m |
| Gross profit | $400.0k | $24.58m | $6.02m | $7.20m |
| Operating income | -$22.79m | -$22.91m | -$23.03m | -$13.65m |
| Net income | $108.83m | -$20.46m | -$17.07m | -$20.19m |
Last four quarters: revenue $46.12m, margin 110.8%, free cash flow -$79.50m
News
8 latest- Abeona Therapeutics (ABEO) Q3 2026 Earnings Call TranscriptThe Motley Fool · 11 hours ago
- Abeona Therapeutics Reports Q3 Net ZEVASKYN Revenue of $13.5 million and Acquisition of ABO-801Fintel · 18 hours ago
- Abeona Therapeutics Inc. Acquires Phase 3-Ready APT-1011 and Enters Into Agreement for $30 Million Private PlacementFintel · 18 hours ago
- Abeona Expands Pipeline With Phase 3-Ready EoE Drug Candidate, Raises $30 Million; Stock Down RTTNews · 20 hours ago
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study RTTNews · Sep 25, 2026
- Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. WainwrightMarketBeat · Sep 22, 2026
- Abeona Expands ZEVASKYN Network as RDEB Launch Gains MomentumMarketBeat · Sep 22, 2026
- Abeona Therapeutics (ABEO) Highlights FDA Approval Of FAYUVI Gene Therapy For MPS IIIA RTTNews · Sep 18, 2026
The company
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona's investigational autologous cell-based gene therapy currently in development for recessive dystrophic epidermolysis bullosa. The Company's fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company's development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona's novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- abeonatherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.